# Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

> **NCT00849290** · PHASE2 · COMPLETED · sponsor: **Dendreon** · enrollment: 113 (actual)

## Conditions studied

- Metastatic Androgen Independent Prostate Cancer

## Interventions

- **BIOLOGICAL:** APC8015F

## Key facts

- **NCT ID:** NCT00849290
- **Lead sponsor:** Dendreon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-01
- **Final completion:** 2009-04
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849290, "Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00849290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*